Catalent (NYSE:CTLT) quickly rose 1% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings ...

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker ...

A Sheffield-based aquaculture biotechnology company says it has been through a “transformational” year after selling one of ...

Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...

Catalent, Inc. (“Catalent”) and Novo Holdings A/S (“Novo Holdings”) jointly announced today the unconditional approval granted by the European Commission (EC) for the pending acquisition transaction ...

The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of Catalent (CTLT) by Novo ...

BRUSSELS, Dec 6 (Reuters) - Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab after EU ...